Vitrolife Ab Stock Current Valuation
| VITR Stock | SEK 224.80 1.20 0.53% |
Valuation analysis of Vitrolife AB helps investors to measure Vitrolife's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Vitrolife's price fluctuation is very steady at this time. Calculation of the real value of Vitrolife AB is based on 3 months time horizon. Increasing Vitrolife's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Vitrolife's intrinsic value may or may not be the same as its current market price of 224.80, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 224.8 | Real 182.09 | Hype 224.8 | Naive 228.96 |
The intrinsic value of Vitrolife's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Vitrolife's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Vitrolife AB helps investors to forecast how Vitrolife stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Vitrolife more accurately as focusing exclusively on Vitrolife's fundamentals will not take into account other important factors: Vitrolife AB Company Current Valuation Analysis
Vitrolife's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Vitrolife Current Valuation | 28.19 B |
Most of Vitrolife's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vitrolife AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Vitrolife AB has a Current Valuation of 28.19 B. This is 96.24% higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The current valuation for all Sweden stocks is 69.55% lower than that of the firm.
Vitrolife Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vitrolife's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vitrolife could also be used in its relative valuation, which is a method of valuing Vitrolife by comparing valuation metrics of similar companies.Vitrolife is currently under evaluation in current valuation category among its peers.
Vitrolife Fundamentals
| Return On Equity | 0.0246 | |||
| Return On Asset | 0.0205 | |||
| Profit Margin | 0.12 % | |||
| Operating Margin | 0.20 % | |||
| Current Valuation | 28.19 B | |||
| Shares Outstanding | 135.45 M | |||
| Shares Owned By Insiders | 32.02 % | |||
| Shares Owned By Institutions | 43.80 % | |||
| Price To Earning | 58.44 X | |||
| Price To Book | 1.61 X | |||
| Price To Sales | 8.73 X | |||
| Revenue | 1.68 B | |||
| Gross Profit | 1.78 B | |||
| EBITDA | 576.66 M | |||
| Net Income | 340.97 M | |||
| Cash And Equivalents | 630.09 M | |||
| Cash Per Share | 4.11 X | |||
| Total Debt | 2.03 B | |||
| Debt To Equity | 4.90 % | |||
| Current Ratio | 4.79 X | |||
| Book Value Per Share | 123.61 X | |||
| Cash Flow From Operations | 384.31 M | |||
| Earnings Per Share | 2.57 X | |||
| Price To Earnings To Growth | 3.50 X | |||
| Target Price | 335.0 | |||
| Number Of Employees | 1.07 K | |||
| Beta | 1.49 | |||
| Market Capitalization | 31.97 B | |||
| Total Asset | 19.43 B | |||
| Retained Earnings | 390 M | |||
| Working Capital | 327 M | |||
| Current Asset | 467 M | |||
| Current Liabilities | 140 M | |||
| Z Score | 9.0 | |||
| Annual Yield | 0 % | |||
| Five Year Return | 0.56 % | |||
| Net Asset | 19.43 B | |||
| Last Dividend Paid | 0.85 |
About Vitrolife Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vitrolife AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vitrolife using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vitrolife AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Vitrolife Stock Analysis
When running Vitrolife's price analysis, check to measure Vitrolife's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vitrolife is operating at the current time. Most of Vitrolife's value examination focuses on studying past and present price action to predict the probability of Vitrolife's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vitrolife's price. Additionally, you may evaluate how the addition of Vitrolife to your portfolios can decrease your overall portfolio volatility.